Cargando…

Blood leukocytes from benznidazole-treated indeterminate chagas disease patients display an overall type-1-modulated cytokine profile upon short-term in vitro stimulation with trypanosoma cruzi antigens

BACKGROUND: Benznidazole (Bz)-chemotherapy is recommended to prevent Chagas disease progression, despite its limited efficacy during chronic disease. However, the host mechanisms underlying these benefits still remain to be elucidated. METHODS: In this study, we have used short-term whole blood cult...

Descripción completa

Detalles Bibliográficos
Autores principales: Sathler-Avelar, Renato, Vitelli-Avelar, Danielle Marquete, Elói-Santos, Silvana Maria, Gontijo, Eliane Dias, Teixeira-Carvalho, Andréa, Martins-Filho, Olindo Assis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3519593/
https://www.ncbi.nlm.nih.gov/pubmed/22625224
http://dx.doi.org/10.1186/1471-2334-12-123
_version_ 1782252695035314176
author Sathler-Avelar, Renato
Vitelli-Avelar, Danielle Marquete
Elói-Santos, Silvana Maria
Gontijo, Eliane Dias
Teixeira-Carvalho, Andréa
Martins-Filho, Olindo Assis
author_facet Sathler-Avelar, Renato
Vitelli-Avelar, Danielle Marquete
Elói-Santos, Silvana Maria
Gontijo, Eliane Dias
Teixeira-Carvalho, Andréa
Martins-Filho, Olindo Assis
author_sort Sathler-Avelar, Renato
collection PubMed
description BACKGROUND: Benznidazole (Bz)-chemotherapy is recommended to prevent Chagas disease progression, despite its limited efficacy during chronic disease. However, the host mechanisms underlying these benefits still remain to be elucidated. METHODS: In this study, we have used short-term whole blood cultures to describe the cytokine profile of Bz-treated Indeterminate Chagas disease patients-(INDt) as compared to untreated patients-(IND). RESULTS: Our findings showed that IND presented increased levels of IL-10(+)neutrophils, IL-12(+) and IL-10(+)monocytes and IFN-γ(+)NK-cells. Moreover, IND showed slight increase of IL-4(+)CD4(+)T-cells and enhanced levels of IL-10(+)CD8(+)T-cells and B-cells. Additional analysis of cytokine Low and High producers also highlighted the presence of High cytokine producers within IND, including IL-10 from CD4+ T-cells and IFN-γ from CD8(+) T-cells, as compared to NI. The Bz-treatment lead to an overall cytokine down-regulation in the innate and adaptive compartments, including low levels of IL-12(+) and IL-10(+)neutrophils and monocytes, IFN-γ(+)NK-cells, IL-12(+), TNF-α(+), IFN-γ(+) and IL-5(+)CD4(+)T-cells and IL-10(+)B-cells, along with basal levels of cytokine-expressing CD8(+)T-cells in INDt as compared to IND. The in vitro antigen stimulation shifted the cytokine profile toward a type 1-modulated profile, with increased levels of IL-12(+) and IL-10(+) monocytes, IFN-γ(+) and IL-4(+)NK-cells along with TNF-α(+) and IFN-γ(+)CD8(+)T-cells. Analysis of Low and High cytokine producers, upon in vitro antigen stimulation, further confirm these data. CONCLUSION: Together, our findings showed that the Bz treatment of Indeterminate Chagas’ disease patients shifts the cytokine patterns of peripheral blood monocytes, NK-cells and CD8(+) T-cells towards a long-lasting Type-1-modulated profile that could be important to the maintenance of a non-deleterious immunological microenvironment.
format Online
Article
Text
id pubmed-3519593
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-35195932012-12-12 Blood leukocytes from benznidazole-treated indeterminate chagas disease patients display an overall type-1-modulated cytokine profile upon short-term in vitro stimulation with trypanosoma cruzi antigens Sathler-Avelar, Renato Vitelli-Avelar, Danielle Marquete Elói-Santos, Silvana Maria Gontijo, Eliane Dias Teixeira-Carvalho, Andréa Martins-Filho, Olindo Assis BMC Infect Dis Research Article BACKGROUND: Benznidazole (Bz)-chemotherapy is recommended to prevent Chagas disease progression, despite its limited efficacy during chronic disease. However, the host mechanisms underlying these benefits still remain to be elucidated. METHODS: In this study, we have used short-term whole blood cultures to describe the cytokine profile of Bz-treated Indeterminate Chagas disease patients-(INDt) as compared to untreated patients-(IND). RESULTS: Our findings showed that IND presented increased levels of IL-10(+)neutrophils, IL-12(+) and IL-10(+)monocytes and IFN-γ(+)NK-cells. Moreover, IND showed slight increase of IL-4(+)CD4(+)T-cells and enhanced levels of IL-10(+)CD8(+)T-cells and B-cells. Additional analysis of cytokine Low and High producers also highlighted the presence of High cytokine producers within IND, including IL-10 from CD4+ T-cells and IFN-γ from CD8(+) T-cells, as compared to NI. The Bz-treatment lead to an overall cytokine down-regulation in the innate and adaptive compartments, including low levels of IL-12(+) and IL-10(+)neutrophils and monocytes, IFN-γ(+)NK-cells, IL-12(+), TNF-α(+), IFN-γ(+) and IL-5(+)CD4(+)T-cells and IL-10(+)B-cells, along with basal levels of cytokine-expressing CD8(+)T-cells in INDt as compared to IND. The in vitro antigen stimulation shifted the cytokine profile toward a type 1-modulated profile, with increased levels of IL-12(+) and IL-10(+) monocytes, IFN-γ(+) and IL-4(+)NK-cells along with TNF-α(+) and IFN-γ(+)CD8(+)T-cells. Analysis of Low and High cytokine producers, upon in vitro antigen stimulation, further confirm these data. CONCLUSION: Together, our findings showed that the Bz treatment of Indeterminate Chagas’ disease patients shifts the cytokine patterns of peripheral blood monocytes, NK-cells and CD8(+) T-cells towards a long-lasting Type-1-modulated profile that could be important to the maintenance of a non-deleterious immunological microenvironment. BioMed Central 2012-05-24 /pmc/articles/PMC3519593/ /pubmed/22625224 http://dx.doi.org/10.1186/1471-2334-12-123 Text en Copyright ©2012 Sathler-Avelar et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Sathler-Avelar, Renato
Vitelli-Avelar, Danielle Marquete
Elói-Santos, Silvana Maria
Gontijo, Eliane Dias
Teixeira-Carvalho, Andréa
Martins-Filho, Olindo Assis
Blood leukocytes from benznidazole-treated indeterminate chagas disease patients display an overall type-1-modulated cytokine profile upon short-term in vitro stimulation with trypanosoma cruzi antigens
title Blood leukocytes from benznidazole-treated indeterminate chagas disease patients display an overall type-1-modulated cytokine profile upon short-term in vitro stimulation with trypanosoma cruzi antigens
title_full Blood leukocytes from benznidazole-treated indeterminate chagas disease patients display an overall type-1-modulated cytokine profile upon short-term in vitro stimulation with trypanosoma cruzi antigens
title_fullStr Blood leukocytes from benznidazole-treated indeterminate chagas disease patients display an overall type-1-modulated cytokine profile upon short-term in vitro stimulation with trypanosoma cruzi antigens
title_full_unstemmed Blood leukocytes from benznidazole-treated indeterminate chagas disease patients display an overall type-1-modulated cytokine profile upon short-term in vitro stimulation with trypanosoma cruzi antigens
title_short Blood leukocytes from benznidazole-treated indeterminate chagas disease patients display an overall type-1-modulated cytokine profile upon short-term in vitro stimulation with trypanosoma cruzi antigens
title_sort blood leukocytes from benznidazole-treated indeterminate chagas disease patients display an overall type-1-modulated cytokine profile upon short-term in vitro stimulation with trypanosoma cruzi antigens
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3519593/
https://www.ncbi.nlm.nih.gov/pubmed/22625224
http://dx.doi.org/10.1186/1471-2334-12-123
work_keys_str_mv AT sathleravelarrenato bloodleukocytesfrombenznidazoletreatedindeterminatechagasdiseasepatientsdisplayanoveralltype1modulatedcytokineprofileuponshortterminvitrostimulationwithtrypanosomacruziantigens
AT vitelliavelardaniellemarquete bloodleukocytesfrombenznidazoletreatedindeterminatechagasdiseasepatientsdisplayanoveralltype1modulatedcytokineprofileuponshortterminvitrostimulationwithtrypanosomacruziantigens
AT eloisantossilvanamaria bloodleukocytesfrombenznidazoletreatedindeterminatechagasdiseasepatientsdisplayanoveralltype1modulatedcytokineprofileuponshortterminvitrostimulationwithtrypanosomacruziantigens
AT gontijoelianedias bloodleukocytesfrombenznidazoletreatedindeterminatechagasdiseasepatientsdisplayanoveralltype1modulatedcytokineprofileuponshortterminvitrostimulationwithtrypanosomacruziantigens
AT teixeiracarvalhoandrea bloodleukocytesfrombenznidazoletreatedindeterminatechagasdiseasepatientsdisplayanoveralltype1modulatedcytokineprofileuponshortterminvitrostimulationwithtrypanosomacruziantigens
AT martinsfilhoolindoassis bloodleukocytesfrombenznidazoletreatedindeterminatechagasdiseasepatientsdisplayanoveralltype1modulatedcytokineprofileuponshortterminvitrostimulationwithtrypanosomacruziantigens